Interictal type 1 cannabinoid receptor binding is increased in female migraine patients

Headache

Volumn 52, Issue 3, 2012, Pages 433-440

  Van Der Schueren, Bart J ^a   Van Laere, Koen ^a   Gérard, Nathalie ^a   Bormans, Guy ^a   De Hoon, Jan N ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

endocannabinoid system; migraine; positron emission tomography imaging

Indexed keywords

CANNABINOID 1 RECEPTOR; FLUORODEOXYGLUCOSE F 18; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TRIPTAN DERIVATIVE;

ADULT; AGE DISTRIBUTION; ANTERIOR CINGULATE; ARTICLE; BINDING AFFINITY; BODY MASS; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; MESIAL TEMPORAL; MIGRAINE; MODULATION; OBSERVATIONAL STUDY; PAIN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; SUPERIOR FRONTAL CORTEX;

ADULT; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MIGRAINE DISORDERS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRIDINES; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 84858336250     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.02030.x     Document Type: Article

References (22)

1. Russo E,. Cannabis for migraine treatment: The once and future prescription? An historical and scientific review. Pain. 1998; 76: 3-8. (Pubitemid 28304936)
2. Greco R, Mangione AS, Sandrini G, Maccarrone M, Nappi G, Tassorelli C,. Effects of anandamide in migraine: Data from an animal model. J Headache Pain. 2011; 12: 177-183.
3. Greco R, Gasperi V, Maccarrone M, Tassorelli C,. The endocannabinoid system and migraine. Exp Neurol. 2010; 224: 85-91.
4. Greco R, Gasperi V, Sandrini G, et al,. Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat. Cephalalgia. 2010; 30: 296-302.
5. Akerman S, Kaube H, Goadsby PJ,. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004; 309: 56-63. (Pubitemid 38393114)
6. Cupini LM, Bari M, Battista N, et al,. Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia. 2006; 26: 277-281.
7. Akerman S, Holland PR, Goadsby PJ,. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther. 2007; 320: 64-71. (Pubitemid 46025720)
8. Burns HD, Van Laere K, Sanabria-Bohorquez S, et al,. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A. 2007; 104: 9800-9805. (Pubitemid 47175347)
9. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
10. Stewart WF, Lipton RB, Whyte J, et al,. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology. 1999; 53: 988-994. (Pubitemid 29442114)
11. Van Laere K, Casteels C, Dhollander I, et al,. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med. 2010; 51: 1413-1417.
12. Sanabria-Bohorquez SM, Van Laere K,. Quantitative PET imaging of radioligands with slow kinetics in human brain. Eur J Nucl Med Mol Imaging. 2010; 37: 1613-1615.
13. Baeyens A, Goffin T,. European Court of Justice. ECJ 2011/4 18 November 2010 (C-156/09). Eur J Health Law. 2011; 18: 239-241.
14. Van Laere K, Goffin K, Casteels C, et al,. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage. 2008; 39: 1533-1541.
15. Valet M, Sprenger T, Boecker H, et al,. Distraction modulates connectivity of the cingulo-frontal cortex and the midbrain during pain-an fMRI analysis. Pain. 2004; 109: 399-408. (Pubitemid 38638717)
16. Lorenz J, Minoshima S, Casey KL,. Keeping pain out of mind: The role of the dorsolateral prefrontal cortex in pain modulation. Brain. 2003; 126: 1079-1091. (Pubitemid 36522951)
17. Juhasz G, Lazary J, Chase D, et al,. Variations in the cannabinoid receptor 1 gene predispose to migraine. Neurosci Lett. 2009; 461: 116-120.
18. Russo EB,. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2004; 25: 31-39. (Pubitemid 44783354)
19. Sarchielli P, Pini LA, Coppola F, et al,. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007; 32: 1384-1390. (Pubitemid 46788851)
20. Cady R, Dodick DW,. Diagnosis and treatment of migraine. Mayo Clin Proc. 2002; 77: 255-261. (Pubitemid 34177601)
21. Wang H, Dey SK, Maccarrone M,. Jekyll and Hyde: Two faces of cannabinoid signaling in male and female fertility. Endocr Rev. 2006; 27: 427-448. (Pubitemid 44213226)
22. Leterrier C, Laine J, Darmon M, Boudin H, Rossier J, Lenkei Z,. Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors. J Neurosci. 2006; 26: 3141-3153.